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sured by cardiac catheterization in patients with severe AS without other
valve disease. 
Methods and results From January 2010 to December 2012, we included
85 consecutive patients with severe AS scheduled for clinically indicated car-
diac catheterization study. Comprehensive transthoracic echocardiography
(TTE) was performed in all patients within 24 hours of the hemodynamic
study. Mean age was 75±9 years, 65% of them were male, 65%, 22% and
54% had respectively a history of hypertension, diabetes, and dyslipidemia.
NYHA functional class was ≥III in 63% of patients. By TTE, mean LV ejec-
tion fraction, max left atrial (LA) volume indexed, were respectively 60±9%,
and 38±16mL/m2. Mean mitral septal E/e’ ratio was 18.6±9. Cardiac cathe-
terization found 60% cases of coronary artery disease and the mean PCWP
was 13.5±7mmHg. As compared to patients with low PCWP (<13mmHg),
those with higher PCWP had similar LVEF, and AS severity but significantly
higher LA indexed volume (41±19 vs. 29±10mL/m2, p=0.004) and septal E/e’
(22.4±10 vs. 14.7±5, p=0.001). A maximal LA indexed volume >29ml/m2 pre-
dicted a PCWP>13mmhg with a sensitivity of 77% and a specificity of 62%
(area under the curve=0.73). Similarly, mitral annular septal E/e’ >12 pre-
dicted PCP>13mmHg with a sensitivity of 90% and a specificity of 60% (area
under the curve=0.73).
Conclusion In severe AS patients, maximal LA indexed volume >29/ml/m2
and E/e’ ratio >12, derived from TTE, appear as good markers of elevated
PCWP. Further studies are needed to investigate their prognostic values.
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Background Identifying subgroups of asymptomatic patients with aortic
stenosis (AS) who may benefit from early intervention is a critical challenge
due to the risk of sudden death and irreversible myocardial dysfunction
without preceding symptoms. In this study, we analyzed the determinants and
prognostic value of Galectin-3 in a large cohort of patients with AS.
Methods We included patients with at least mild degenerative AS enrolled
in 2 ongoing prospective clinical studies, COFRASA and GENERAC, aiming
at assessing the determinants of AS occurrence and progression.
Results Between November 2006 and July 2013, 583 patients were pro-
spectively enrolled. Severe AS was diagnosed in 312 (56%) patients
among whom 220 (38%) were symptomatic. Age (p<0.0001) and reduced
creatinine clearance (p<0.0001) were positively associated with Galectin-
3 level. 
No significant association was found between Galectin-3 and echocardio-
graphic parameters of AS severity including aortic valve area (p=0.41), mean
transvalvular gradient (p=0,27), and AS jet velocity (p=0.52). Galectin-3 did
not provide diagnostic evidence of severe AS (area under the curve=0.53).
Galectin-3 was not influenced by symptomatic status. Echocardiographic
parameters of LV remodeling were not associated with Galectin-3 in multivar-
iate analysis. Event-free survival analysis revealed no prognostic value of
Galectin-3.
Conclusions The main determinants of Galectin-3 level were age and renal
function. There was no association between Galectin-3 and symptomatic
status and echocardiographic parameters associated with LV remodeling.
Galectin-3 didn’t provide prognostic information on the occurrence of AS
related events. These results do not support the use of Galectin-3 in the deci-
sion making process of patients with AS.
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Background Percutaneous mitral valvuloplasty (PMV) has emerged as the
procedure of choice in treatment of mitral stenosis and has proved effective-
ness in cases of mitral restenosis after surgical commissurotomy Compared
with surgery, PMV is associated with shorter hospital stays, reduced patient
discomfort, and significantly lower costs. However, it is unknown whether
patients who developed symptomatic mitral restenosis after PMV may benefit
from repeat PMV (re-PMV) with safety.
Objectives This study was designed to evaluate the occurrence rate and the
predictive factors for severe complications following re-PMV.
Methods Retrospective study from a series of 40 procedures of re-PMV
with the Inoue balloon at 8±4 years after prior procedure, performed between
1996 and 2011. A clinical and ultrasound follow-up was achieved in
31 patients with a mean follow-up period of 43±26 months.
Results The mean age of patients was 43±11 years [23, 63]. 87.5% of the
population being female (5 men and 35 women). The immediate procedural
success was achieved in 31 patients (77.5%). A severe mitral regurgitation
(MR) was observed in 3 patients (7.5%). A cerebrovascular stroke occurred in
1 patient (2.5%). No procedure-related death or cardiac tamponade were
noted. Only a left atrial area ≤25cm 2 was linked to high risk of severe MR. At
long-term, mitral restenosis was observed in 13 patients (42%) at 53±30
months [9; 128] after re-PMV, 2 patients presented thromboembolic events
(6%) and no death. Only the male had been identified as a predictor of
restenosis.
Conclusion: The feasibility of re – PMV with a relatively high procedural
success rate and an acceptable complication profile makes it an appealing
therapeutic strategy for patients with recurrent valve stenosis.
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Aims The aim of this study is to demonstrate efficacy and safety of a new
technique for rapid pacing during balloon aortic valvuloplasty (BAV) and
Transaortic Valve Implantation (TAVI).
This study first describes the method used safely and successfully for BAV
and TAVI in a fragile adult population.
Methods and results these technique consist in a left ventricular pacing
through the 0.35 inch back up guidewire inserted into the left ventricule. The
cathode of an external pacemaker was placed on the external end of the 0.35’
wire using an alligator clamp. The anode was placed (also using an alligator
clamp) on a small needle piercing the subcutaneous tissue at the site of the
anesthetized groin.
The balloon or the TAVI catheter provides the necessary insulation.
We performed consecutively 100 cases of BAV and TAVI. All cases were
successfully conducted with a one for one pacing (160 to 200/mn). That’s how
we obtain a significant blood pressure drop in all cases with a mean systolic
pressure during stimulation of 45mmHg. The time procedure was 38mn for
BAV and 65mn for TAVI. Only three patients underwent a venous temporary
pacemaker at the end of procedure for conduction disturbances. All cases of
TAVI (34) underwent a femoral venous catheter as a central catheter while the
BAV population did not have a venous femoral puncture. No venous vascular
complication or tamponade was observed in our population.
